{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:17:36Z","timestamp":1783124256964,"version":"3.54.6"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560588"],"award-info":[{"award-number":["82560588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260720"],"award-info":[{"award-number":["82260720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010251","name":"Youth Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20242BAB21022"],"award-info":[{"award-number":["20242BAB21022"]}],"id":[{"id":"10.13039\/501100010251","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20253BAC28004"],"award-info":[{"award-number":["20253BAC28004"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009102","name":"Jiangxi Provincial Department of Education","doi-asserted-by":"publisher","award":["20244BCE52227"],"award-info":[{"award-number":["20244BCE52227"]}],"id":[{"id":"10.13039\/501100009102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102769","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:42:58Z","timestamp":1776955378000},"page":"102769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt\/\u03b2-catenin signaling"],"prefix":"10.1016","volume":"7","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2019an","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-2682","authenticated-orcid":false,"given":"Shuyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102769_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102769_bib2","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102769_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021702","article-title":"Current Targeted Therapy for Metastatic Colorectal Cancer","volume":"24","author":"Ohishi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102769_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic landscape and future direction of metastatic colorectal cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.102769_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jso.27295","article-title":"Colorectal cancer: Review of signaling pathways and associated therapeutic strategies","volume":"127","author":"Leiphrakpam","year":"2023","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xcrm.2026.102769_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: Biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102769_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"key":"10.1016\/j.xcrm.2026.102769_bib9","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Morgenstern-Kaplan","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2026.102769_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ddr.21870","article-title":"Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors","volume":"82","author":"Liao","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: Recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102769_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102769_bib17","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102769_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447280","article-title":"Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102769_bib19","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102769_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(24)01045-6","article-title":"Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial","volume":"404","author":"Ergun","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102769_bib21","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib23","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib25","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xcrm.2026.102769_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.102769_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050652","article-title":"Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs","volume":"17","author":"Jiang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xcrm.2026.102769_bib30","article-title":"Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","article-title":"Endoplasmic reticulum stress: molecular mechanism and therapeutic targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102769_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.trecan.2016.03.007","article-title":"Endoplasmic Reticulum Stress and the Hallmarks of Cancer","volume":"2","author":"Urra","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib33","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2022.06.006","article-title":"Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity","volume":"8","author":"Salvagno","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib34","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.trecan.2024.09.011","article-title":"The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment","volume":"10","author":"Urra","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1078-0432.CCR-13-3239","article-title":"Molecular pathways: the PERKs and pitfalls of targeting the unfolded protein response in cancer","volume":"21","author":"Maas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70263","article-title":"Endoplasmic Reticulum Stress in Cancer","volume":"6","author":"Zhou","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.xcrm.2026.102769_bib37","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1021\/jm300713s","article-title":"Discovery of 7-methyl-5-(1-[3-(trifluoromethyl)phenyl]acetyl-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)","volume":"55","author":"Axten","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102769_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102864","article-title":"Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity","volume":"12","author":"Bagratuni","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2026.102769_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omto.2020.01.001","article-title":"The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism","volume":"16","author":"McLaughlin","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102769_bib40","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","article-title":"Towards precision oncology with patient-derived xenografts","volume":"19","author":"Zanella","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.celrep.2016.05.071","article-title":"Direct Targeting of beta-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt\/beta-Catenin Signaling","volume":"16","author":"Hwang","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102769_bib43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cr.2011.127","article-title":"Small molecule-based disruption of the Axin\/beta-catenin protein complex regulates mesenchymal stem cell differentiation","volume":"22","author":"Gwak","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib44","article-title":"Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer","volume":"4","author":"Tan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41573-025-01317-y","article-title":"Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges","volume":"25","author":"Wang","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102769_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102769_bib47","article-title":"Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096993","article-title":"Trop-2 is a determinant of breast cancer survival","volume":"9","author":"Ambrogi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102769_bib49","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/cdd.2017.58","article-title":"When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157","volume":"24","author":"Rojas-Rivera","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2026.102769_bib50","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s10147-024-02589-x","article-title":"Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","volume":"29","author":"Naito","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70562","article-title":"Feedback regulation between histone H3 lysine 18 lactylation and TROP2-mediated glycolysis drives metastatic progression of colorectal cancer","volume":"16","author":"Wang","year":"2026","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib52","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","article-title":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study","volume":"43","author":"Zhong","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102769_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.xcrm.2026.102769_bib54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.xcrm.2026.102769_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.102769_bib57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40364-025-00813-y","article-title":"Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression","volume":"13","author":"Unal","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.102769_bib58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41420-025-02862-6","article-title":"Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment","volume":"11","author":"Chai","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xcrm.2026.102769_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature13119","article-title":"XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway","volume":"508","author":"Chen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102769_bib60","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41418-024-01378-3","article-title":"Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway","volume":"31","author":"A Avelar","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2026.102769_bib61","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.celrep.2017.09.072","article-title":"USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating beta-Catenin Deubiquitination","volume":"21","author":"Novellasdemunt","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102769_bib62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41580-024-00823-y","article-title":"Mechanistic insights into Wnt-beta-catenin pathway activation and signal transduction","volume":"26","author":"Maurice","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102769_bib63","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-022-01616-7","article-title":"Wnt signaling in colorectal cancer: pathogenic role and therapeutic target","volume":"21","author":"Zhao","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","article-title":"Wnt\/beta-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy","volume":"24","author":"Wu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s12967-024-05380-8","article-title":"Wnt\/beta-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102769_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"van Aken","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102769_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011279","article-title":"Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic","volume":"13","author":"Eguren-Santamaria","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib68","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102769_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abb4749","article-title":"Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice","volume":"13","author":"Hughes","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2026.102769_bib70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2019.02.002","article-title":"Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma","volume":"448","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102769_bib71","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00432-022-03928-z","article-title":"Expression and clinical prognostic value of CYB561 in breast cancer","volume":"148","author":"Zhou","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:28:45Z","timestamp":1783121325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001862"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102769","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt\/\u03b2-catenin signaling","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102769"}}